Foghorn Therapeutics Inc.
FHTX Nasdaq· Pharmaceutical Preparations
Last close · Oct 27, 2026
$2.05
KIRA · Stoqly’s AI analyst, in plain words
- Foghorn Therapeutics Inc. had $30.9M of revenue in fiscal 2025, up 36.8% on the year before. Over five years, revenue changed +135.1% a year on average.
- Its operating margin was −279.5%, up 174.8 pts: of every 100 in sales, about −279 is left after running the business.
- Foghorn Therapeutics Inc. lost $74.3M in fiscal 2025.
- Free cash flow was −$86.1M in fiscal 2025, −278.7% of revenue.
Market cap
$145M
P/E
—
Revenue
$30.9M
Net income
−$74.3M
Free cash flow
−$86.1M
Operating margin
−279.5%
Foghorn Therapeutics Inc. in 30 seconds · fiscal 2025
Are sales growing?
+36.8%
Yes. Sales grew 36.8% last year.
Does it make a profit?
−240.3%
No. It lost money last year.
Does profit turn into cash?
−278.7%
No. It spent more cash than it brought in.
How healthy are the accounts?
1 / 7
Weak. It passes 1 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Foghorn Therapeutics Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 11, 2026
- Legal name
- Foghorn Therapeutics Inc.
- CIK
- 0001822462
Foghorn Therapeutics Inc. · FHTX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $1.3M | $19.2M | $34.2M | $22.6M | $30.9M |
| Revenue growth | 206.7% | 1,357.8% | 77.6% | −33.8% | 36.8% |
| Operating margin | −7,637.1% | −609.2% | −315.9% | −454.3% | −279.5% |
| Net income | −$101M | −$109M | −$98.4M | −$86.6M | −$74.3M |
| Net margin | −7,681.6% | −566.3% | −288.2% | −383.2% | −240.3% |
| Diluted EPS | −$2.73 | −$2.62 | −$2.34 | −$1.58 | −$1.18 |
| Cash | |||||
| Cash from operations | −$50.3M | $194M | −$118M | −$100M | −$86.1M |
| Capital expenditure | $3.3M | $1.2M | $1.2M | $0.9M | $0.1M |
| Free cash flow | −$53.6M | $192M | −$119M | −$101M | −$86.1M |
| FCF margin | −4,060.9% | 1,000.6% | −349.4% | −448.2% | −278.7% |
| Share count change | 236.5% | 11.9% | 0.9% | 30.8% | 14.7% |
| Debt and strength | |||||
| Cash and short-term investments | $101M | $52.2M | $80.3M | $55.5M | $80.9M |
| Debt incl. finance leases | $0.0M | — | — | — | — |
| Shareholders' equity | $96.9M | $0.1M | −$77.2M | −$45.5M | −$109M |
| Current ratio | 9.4x | 6.4x | 4.1x | 3.7x | 2.7x |
| Interest coverage | −52.9x | — | — | — | — |
| Returns and quality | |||||
| Return on equity | −83.4% | −224.5% | — | — | — |
| Return on tangible equity | −104.6% | −97,216.1% | — | — | — |
| Piotroski F-score | 4 | 3 | 1 | 1 | 1 |
| Altman Z'' | 2.5 | −0.1 | −4.0 | −4.8 | −10.3 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Foghorn Therapeutics Inc. · FHTX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $2.05 a share, the company is worth $145M.
Source: SEC EDGAR XBRL filings (CIK 0001822462). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.